Short Interest in Bone Biologics Corp. (NASDAQ:BBLG) Declines By 72.2%

Bone Biologics Corp. (NASDAQ:BBLG) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,897 shares, a decrease of 72.2% from the April 30th total of 10,427 shares. Based on an average daily volume of 9,614 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are short sold.

Bone Biologics Stock Performance

Shares of NASDAQ BBLG opened at $1.31 on Friday. The firm has a market cap of $2.35 million, a price-to-earnings ratio of -0.57 and a beta of 0.89. The business’s 50-day simple moving average is $1.26 and its 200-day simple moving average is $1.44. Bone Biologics has a 52 week low of $1.05 and a 52 week high of $6.75.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) EPS for the quarter, meeting analysts’ consensus estimates of ($0.43). As a group, equities research analysts forecast that Bone Biologics will post -1.52 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the SEC. 34.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings raised Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics has an average rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.